Recursion Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 4.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.41B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat ...